Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
Checked against the public recordLast updated Jan 23, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Crizotinib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * histologically or cytologically proven diagnosis of malignancy other than NSCLC * positive for translocation or inversion event involving the ALK gene locus * positive for ALK amplification events * positive for ALK activating point mutations Exclusion Criteria: * mutations of amplifications involving the c-Met gene but not the ALK gene * concurrent treatment on another therapeutic clinical trial * prior therapy specifically directed against ALK
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Highlands Oncology GroupFayetteville, Arkansas
- Highlands Oncology GroupRogers, Arkansas
- Highland Oncology GroupSpringdale, Arkansas
- Washington University School of MedicineSt Louis, Missouri
- Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
- OHSU Center for Health and Healing 2Portland, Oregon
- Oregon Health & Science UniversityPortland, Oregon
- Oregon Health and Science UniversityPortland, Oregon
- Greenville Health System, Institute for Translational Oncology ResearchGreenville, South Carolina
- Cancer Institute and Hospital, Chinese Academy of Medical SciencesBeijing, Chaoyang District
- SUN Yat-Sen University Cancer CenterGuangzhou, Guangdong
- Centro di Ricerca di Fase 1 ASST-MonzaMonza
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 23, 2025. Always confirm current availability with the study team.